Trial Search Results
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
Stanford is currently not accepting patients for this trial.
- Drug: Fostamatinib 150 mg
- Drug: Fostamatinib 100 mg
- Drug: Placebo
- Renal biopsy findings consistent with IgA nephropathy
- Treatment with an Angiotensin Converting Enzyme inhibitor (ACEi) and/or an Angiotensin
II Receptor Blocker (ARB) for at least 90 days at the maximum approved (or tolerated)
- Proteinuria > 1 gm/day at diagnosis of IgA nephropathy and Proteinuria > 0.50 gm/day
at the second Screening Visit
- Blood pressure controlled to ≤ 130/80 with angiotensin blockade with or without other
- Recent use of cyclophosphamide, mycophenolate mofetil, azathioprine, or Rituximab.
- Use of > 15 mg/day prednisone (or other corticosteroid equivalent).
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study